Lingtao Jin, PhD

Lingtao Jin

Assistant Professor

Office: CGRC 356
Phone: (352) 273-6953

Education and Training

PhDPharmacology, Institute of Biophysics, Chinese Academy of Sciences, China 2010
BSBio-engineering, Shenyang Pharmaceutical University, China 2004

Postdoctoral Training

Postdoctoral FellowCancer metabolism, Dept. Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia

Research Interests

Our research interest is focused on understanding the signaling basis of cancer metabolism, particularly the function of metabolic enzymes and onco-metabolites in cancer and drug resistance. An ultimate goal is to identify metabolic vulnerabilities in cancer and apply the obtained insights to the development of molecular-targeted therapies to treat human cancers

Ongoing Research Support

  1. Elsa U. Pardee Foundation Research Grant
  2. Breast Cancer Research Foundation-AACR Career Development Award for Translational Breast Cancer Research
  3. UF Health Cancer Center Pilot Project

Professional Societies

American Association for Cancer Research (AACR): 2012 – Present


Chun J, Li D, Pan C, Boese A, Song L, Magliocca K, Chen Z, Saba N, Shin D, Owonikoko T, Lonial S, Jin L*, and Kang S*. Hsp90 beta protects MAST1 from CHIP-mediated ubiquitination and degradation providing cisplatin resistance. (2019). Journal of Clinical Investigation, In press. (*Corresponding author).

Pan C, Jin L, Wang X, Li Y, Chun J, Boese AC, Li D, Kang HB, Zhang G, Zhou L, Chen GZ, Saba NF, Shin DM, Magliocca KR, Owonikoko TK, Mao H, Lonial S, Kang S. Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. (2019). Journal of Clinical Investigation, 129(6):2431-2445 | PubMed

Ni F, Yu WM, Li Z, Graham DK, Jin L, Kang S, Rossi MR, Li S4, Broxmeyer HE, Qu CK. Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression. (2019). Nature Metabolism. 1(3):390-403. | PubMed

Jin L, Chun J, Pan C, Li D, Lin R, Alesi GN, Wang X, Kang HB, Song L, Wang D, Zhang G, Fan J, Boggon TJ, Zhou L, Kowalski J, Qu CK, Steuer CE, Chen GZ, Saba NF, Boise LH, Owonikoko TK, Khuri FR, Magliocca KR, Shin DM, Lonial S, Kang S. MAST1 drives cisplatin resistance in human cancers by rewiring cRaf independent MEK activation. (2018). Cancer Cell, 34(2):315-330.-Featured in: Cancer Cell. 34(2):183-185 | PubMed

Zeng W, Jin L*, Zhang F, Zhang C, and Liang W*. Naringenin as a Potential Immunomodulator in Therapeutic. (2018). Pharmacological Research, 135:122-126. | | (*Corresponding author)

Jin L*, Chun J, Pan C, Kumar A, Zhang G, Ha Y, Li Dan, Alesi GN, Kang Y, Zhou L, Yu W-W, Magliocca KR, Khuri FR, Qu C-K, Metallo C, Owonikoko TK and Kang S*. The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. (2017). Molecular Cell 69(1):87-99 | PubMed | (*Corresponding author) – Featured in: Molecular Cell 69(1):1-2

Jin L, Zeng W, Zhang F, Zhang C, Liang W. Naringenin ameliorates acute inflammation by regulating intracellular cytokine degradation. (2017). Journal of Immunology 199(10):3466-3477. | PubMed

Jin L*, Chun J*, Pan C, Alesi GN, Li D, Magliocca KR, Kang Y, Chen ZG, Shin DM, Khuri FR, Fan J, Kang S. Y10 phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumor metastasis. (2017). Oncogene 36(27):3797-3806. | PubMed | (*Co-first author)

Jin L*, Alesi GN, Kang S*. Glutaminolysis as a target for cancer therapy. (2016). Oncogene 35(28):3619-25. | PubMed | (*Corresponding author)

Jin L, Li D, Alesi GN, Fan J, Kang HB, Lu Z, Boggon TJ, Jin P, Yi H, Wright ER, Duong D, Seyfried NT, Egnatchik R, DeBerardinis RJ, Magliocca KR, He C, Arellano ML, Khoury HJ, Shin DM, Khuri FR, Kang S. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. (2015). Cancer Cell 27(2):257-70. | PubMed

Visit Pubmed for a full list of references